Institution
The Chinese University of Hong Kong
Education•Hong Kong, China•
About: The Chinese University of Hong Kong is a education organization based out in Hong Kong, China. It is known for research contribution in the topics: Population & Cancer. The organization has 43411 authors who have published 93672 publications receiving 3066651 citations.
Topics: Population, Cancer, Poison control, Randomized controlled trial, China
Papers published on a yearly basis
Papers
More filters
Taipei Veterans General Hospital1, The Chinese University of Hong Kong2, Mahidol University3, University of Malaya4, South Korean Ministry for Health, Welfare and Family Affairs5, Ajou University6, Khon Kaen University7, Kyung Hee University8, National Cheng Kung University9, Chinese Ministry of Health10, Kyoto University11, University of Tokyo12
TL;DR: The AWGS consensus report is believed to promote more Asian sarcopenia research, and most important of all, to focus on sarc Openia intervention studies and the implementation of sarcopenian in clinical practice to improve health care outcomes of older people in the communities and the healthcare settings in Asia.
2,976 citations
TL;DR: In this paper, the ultimate ownership and control of 5,232 corporations in 13 Western European countries were analyzed, and the majority of firms were either widely held (36.93%) or family controlled (44.29%).
2,934 citations
Jeffrey D. Stanaway1, Ashkan Afshin1, Emmanuela Gakidou1, Stephen S Lim1 +1050 more•Institutions (346)
TL;DR: This study estimated levels and trends in exposure, attributable deaths, and attributable disability-adjusted life-years (DALYs) by age group, sex, year, and location for 84 behavioural, environmental and occupational, and metabolic risks or groups of risks from 1990 to 2017 and explored the relationship between development and risk exposure.
2,910 citations
Harvard University1, University of California, San Francisco2, University of Amsterdam3, Northwestern University4, International Agency for Research on Cancer5, Aix-Marseille University6, University of Toronto7, The Chinese University of Hong Kong8, German Cancer Research Center9, University of Düsseldorf10, University of Turin11, Heidelberg University12, St. Jude Children's Research Hospital13
TL;DR: The fifth edition of the WHO Classification of Tumors of the Central Nervous System (CNS), published in 2021, is the sixth version of the international standard for the classification of brain and spinal cord tumors as mentioned in this paper.
Abstract: The fifth edition of the WHO Classification of Tumors of the Central Nervous System (CNS), published in 2021, is the sixth version of the international standard for the classification of brain and spinal cord tumors. Building on the 2016 updated fourth edition and the work of the Consortium to Inform Molecular and Practical Approaches to CNS Tumor Taxonomy, the 2021 fifth edition introduces major changes that advance the role of molecular diagnostics in CNS tumor classification. At the same time, it remains wedded to other established approaches to tumor diagnosis such as histology and immunohistochemistry. In doing so, the fifth edition establishes some different approaches to both CNS tumor nomenclature and grading and it emphasizes the importance of integrated diagnoses and layered reports. New tumor types and subtypes are introduced, some based on novel diagnostic technologies such as DNA methylome profiling. The present review summarizes the major general changes in the 2021 fifth edition classification and the specific changes in each taxonomic category. It is hoped that this summary provides an overview to facilitate more in-depth exploration of the entire fifth edition of the WHO Classification of Tumors of the Central Nervous System.
2,908 citations
University of Navarra1, University of Hong Kong2, Kindai University3, National Taiwan University4, Seoul National University Hospital5, Goethe University Frankfurt6, University of Michigan7, Royal Free Hospital8, Asan Medical Center9, The Chinese University of Hong Kong10, Johns Hopkins University11, Bristol-Myers Squibb12, Chartered Institute of Management Accountants13
TL;DR: Durable objective responses show the potential of nivolumab for treatment of advanced hepatocellular carcinoma, and safety and tolerability for the escalation phase and objective response rate were primary endpoints.
2,908 citations
Authors
Showing all 43993 results
| Name | H-index | Papers | Citations |
|---|---|---|---|
| Michael Marmot | 193 | 1147 | 170338 |
| Jing Wang | 184 | 4046 | 202769 |
| Jiaguo Yu | 178 | 730 | 113300 |
| Yang Yang | 171 | 2644 | 153049 |
| Mark Gerstein | 168 | 751 | 149578 |
| Gang Chen | 167 | 3372 | 149819 |
| Jun Wang | 166 | 1093 | 141621 |
| Jean Louis Vincent | 161 | 1667 | 163721 |
| Wei Zheng | 151 | 1929 | 120209 |
| Rui Zhang | 151 | 2625 | 107917 |
| Ben Zhong Tang | 149 | 2007 | 116294 |
| Kypros H. Nicolaides | 147 | 1302 | 87091 |
| Thomas S. Huang | 146 | 1299 | 101564 |
| Galen D. Stucky | 144 | 958 | 101796 |
| Joseph J.Y. Sung | 142 | 1240 | 92035 |